FDA versus Big Supp: Rep. Burton to the Rescue (Again)

The FDA and Big Supp Enter the Ring

“Big Supp” is an informal nickname for the sprawling dietary supplement industry. It includes major manufacturers, ingredient suppliers, trade associations, retailers, online sellers, and smaller companies offering everything from ordinary multivitamins to products promising heroic improvements in energy, immunity, memory, metabolism, sleep, and other bodily functions that conveniently begin with the letter “m.”

The Food and Drug Administration, meanwhile, is responsible for overseeing dietary supplements sold in the United States. That sentence sounds reassuring until one examines what “overseeing” means under federal law.

Prescription and over-the-counter drugs generally must pass through an FDA review process before reaching consumers. Companies must provide evidence concerning safety, effectiveness, manufacturing, and labeling. Dietary supplements operate under a different system. Except for certain requirements involving new dietary ingredients, manufacturers do not need FDA approval before placing a supplement on the market.

The company is initially responsible for determining that its product is safe and that its labeling is truthful. The FDA often enters the story after marketing begins, particularly when evidence suggests that a product is adulterated, misbranded, illegally promoted as a treatment, or associated with harmful effects.

It is less “show us your homework before class” and more “keep your homework somewhere, and please do not set the classroom on fire.”

How DSHEA Created the Modern Supplement Marketplace

The central law in this story is the Dietary Supplement Health and Education Act of 1994, commonly known as DSHEA. Signed into law on October 25, 1994, DSHEA established a special regulatory framework for vitamins, minerals, herbs, amino acids, concentrates, extracts, and other qualifying dietary ingredients.

Supporters viewed DSHEA as a defense of consumer access. They feared that aggressive FDA regulation could remove familiar vitamins and herbs from store shelves or make supplements prohibitively expensive. The legislation also reflected the idea that consumers should be free to make their own health decisions.

Critics argued that the law placed too much responsibility in the hands of manufacturers and too much investigative burden on an already stretched federal agency. A substance can produce powerful biological effects whether it arrives in a prescription bottle, grows on a hillside, or appears in packaging decorated with leaves and a sunrise.

Structure-and-Function Claims

DSHEA permits manufacturers to make certain claims about how a supplement supports the structure or normal function of the body. A company might say that a product “supports immune function” or “promotes joint health.” It generally cannot legally claim that the same product diagnoses, treats, cures, or prevents a disease unless it satisfies the requirements applicable to drugs or another authorized category of claim.

Products carrying structure-and-function claims must display the familiar disclaimer explaining that the statement has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent disease.

The distinction may be legally meaningful, but it can become fuzzy in the mind of a shopper. “Supports healthy blood sugar” can sound remarkably similar to “helps with diabetes,” especially when accompanied by a photograph of a smiling person jogging through an orchard.

The New Dietary Ingredient Requirement

DSHEA also created a category called a new dietary ingredient, or NDI. In general, an ingredient that was not marketed in the United States as a dietary ingredient before October 15, 1994, may be considered new.

When the law requires an NDI notification, the manufacturer or distributor must notify the FDA at least 75 days before marketing. The submission should explain why a supplement containing the ingredient can reasonably be expected to be safe under its recommended conditions of use.

This is not full drug-style approval. It is a limited premarket safety notification. Even so, compliance became one of the most persistent weak points in the regulatory system. Thousands of products and formulations entered the expanding market, while the number of submitted notifications appeared far smaller than regulators and independent analysts believed the marketplace should have produced.

Why the FDA Issued Its 2011 Draft Guidance

The Food Safety Modernization Act, which became law in January 2011, directed federal health officials to clarify the evidence and procedures associated with new dietary ingredient notifications. In July 2011, the FDA released draft guidance addressing questions such as what qualifies as an NDI, when a notification is required, and what safety information should accompany it.

The document was guidance rather than a new statute. It described the FDA’s interpretation of existing legal requirements and expressly stated that its recommendations were nonbinding. Companies could use alternative methods if those methods satisfied the law.

Nevertheless, parts of the supplement industry reacted as though federal agents were about to rappel through health-food-store skylights and confiscate the vitamin C.

Industry representatives raised legitimate questions about cost, duplication, confidential business information, ingredient combinations, manufacturing changes, and the FDA’s interpretation of chemical alteration. Some companies feared that previously marketed products would suddenly need extensive new submissions.

Other responses went considerably further, portraying the guidance as an attempt to ban supplements or destroy consumer access. That framing transformed a technical argument over safety documentation into a much more marketable conflict: freedom versus government control.

Rep. Dan Burton Rides to the Rescue

Representative Dan Burton, a Republican from Indiana, had long presented himself as a defender of dietary supplements and alternative health practices. On November 4, 2011, he introduced H.R. 3380, the Dietary Supplement Protection Act of 2011.

The proposal’s most consequential provision was only a few lines long. DSHEA generally treated ingredients marketed before October 15, 1994, as existing rather than new dietary ingredients. Burton’s bill would have changed that cutoff date to January 1, 2007.

That alteration would have grandfathered more than 12 additional years of ingredients. Products introduced during that period could potentially avoid the NDI notification requirement that would otherwise have applied.

From the industry-friendly perspective, the proposal offered relief from uncertainty created by the FDA’s interpretation of an old and inconsistently enforced law. If companies had operated for years under a confusing system, supporters argued, it would be unfair to punish them retroactively.

From the consumer-protection perspective, however, the proposal resembled a legislative eraser. Companies that had failed to submit required safety notifications would not have to fill the gap; Congress would simply move the historical boundary until much of the noncompliance disappeared.

Imagine discovering that thousands of drivers had ignored a stop sign and solving the problem by moving the sign 12 blocks down the road. Efficient? Certainly. Reassuring? Not especially.

The Trouble With “Historical Use”

H.R. 3380 relied heavily on the idea that years of consumer use demonstrated safety. Historical experience can provide useful information, but it is not equivalent to a controlled safety evaluation.

Harm may be delayed, uncommon, difficult to diagnose, or mistakenly attributed to another cause. Consumers may take several products simultaneously. Formulations can change while product names remain familiar. Adverse events may never reach manufacturers or the FDA, particularly when they are not classified as serious.

A lack of well-documented reports therefore does not automatically prove that an ingredient is safe. Sometimes it proves only that nobody built a reliable system for detecting the problem.

The bill also described thousands of supplements as having been “approved” by the FDA. That characterization was misleading because the FDA does not approve dietary supplements in the same manner that it approves drugs. The difference is not bureaucratic trivia. It shapes what consumers reasonably believe when they see a product for sale.

Burton’s Broader Health-Freedom Campaign

H.R. 3380 was not Burton’s only involvement in supplement-friendly legislation. He also supported proposals that would have made it more difficult for the FDA or Federal Trade Commission to challenge health claims and advertising.

One proposal sought to place demanding evidentiary and courtroom requirements on FDA enforcement against certain claims. Another would have restricted FTC investigations and shifted a heavier burden onto the agency before it could act against allegedly misleading supplement advertising.

Supporters described such legislation as protection for commercial speech and consumer choice. Critics saw a system in which a company could make an ambitious claim first, collect revenue second, and force regulators into expensive litigation somewhere around step 47.

The FTC’s continuing position is that objective health claims require adequate scientific substantiation. A testimonial, a traditional-use story, or a scientist wearing a white coat in an advertisement does not automatically transform weak evidence into reliable evidence.

What Happened to the Dietary Supplement Protection Act?

H.R. 3380 was referred to the House Committee on Energy and Commerce after its introduction. It went no further and did not become law.

Burton retired from Congress in January 2013, but the policy conflict outlived his congressional career. The FDA later revised its NDI draft guidance, and in 2024 it finalized separate guidance addressing notification procedures and timeframes. The original October 15, 1994, dividing line remains part of the federal framework.

The underlying compliance problem also remains difficult. There is no definitive government list identifying every ingredient that was legally marketed before the cutoff. Manufacturers must determine and document whether an ingredient qualifies as old or new. Meanwhile, the marketplace continues to produce new extracts, concentrated compounds, novel delivery methods, and products assembled from long ingredient lists.

Why Supplement Oversight Still Matters

Dietary supplements are not inherently useless or dangerous. Targeted supplementation can be medically valuable for correcting nutritional deficiencies, supporting particular life stages, or meeting established clinical recommendations. The problem is not the existence of vitamin tablets. The problem is treating every product described as “natural” as though the word were a safety certificate issued by Mother Nature herself.

A widely cited national analysis estimated that supplement-related adverse events accounted for approximately 23,000 emergency department visits and more than 2,000 hospitalizations annually. Weight-loss and energy products were frequently associated with cardiovascular symptoms in younger adults, while large micronutrient pills created swallowing problems for some older adults.

Those figures do not mean supplements are uniquely dangerous compared with medications. They do demonstrate that supplements can cause real harm and deserve a regulatory system capable of detecting it.

Use has also grown. A National Center for Health Statistics report published in May 2026 found that 60.2% of American adults had used at least one dietary supplement during the previous 30 days in the August 2021–August 2023 survey period. Nearly 39% had taken two or more.

When most adults participate in a market, basic transparency is no longer a niche concern for vitamin enthusiasts. It is mainstream public-health infrastructure.

The 2026 Version of the Same Argument

The debate continues in a new form. On April 20, 2026, Representative Maxine Dexter introduced H.R. 8370, the Dietary Supplement Listing Act of 2026. Rather than demanding drug-style premarket approval, the proposal would require manufacturers to list products with the FDA and submit information such as labels and ingredients.

Supporters argue that the FDA cannot efficiently monitor a marketplace when it lacks a comprehensive inventory of products. A listing database could help regulators identify illegal ingredients, connect adverse-event reports with exact formulations, inspect higher-risk facilities, and respond more quickly when a safety signal appears.

Opponents argue that mandatory listing would burden responsible companies, create technical compliance traps, increase costs, and provide little benefit if bad actors simply ignore the requirement.

Interestingly, the supplement industry is not united. Some major trade organizations support a carefully designed listing system, while others oppose it. “Big Supp,” like “Big Pharma,” is a catchy phrase but not a single creature sitting in a boardroom and stroking an enormous bottle of magnesium.

A Better Balance Between Access and Evidence

The strongest policy does not require choosing between unrestricted marketing and treating every bottle of zinc like an experimental cancer drug. A practical middle ground could preserve access while improving accountability.

Require Basic Product Transparency

The FDA should be able to determine which products are being sold, who is responsible for them, where they are manufactured, and what ingredients and dosages they contain. Listing is not approval, but it gives oversight agencies a map instead of asking them to patrol the marketplace with binoculars and optimism.

Strengthen New Ingredient Compliance

Companies introducing genuinely new dietary ingredients should provide meaningful safety information before marketing. Requirements should be clear enough that responsible firms can comply without hiring an archaeologist to interpret the Federal Register.

Make Claims Match the Evidence

Companies should not be able to imply disease treatment through carefully choreographed wording while hiding behind a disclaimer. Consumers generally remember the bold promise, not the sentence printed beneath the asterisk.

Reward Responsible Manufacturers

Better enforcement benefits companies that invest in testing, quality control, accurate labels, and honest advertising. Weak oversight allows low-quality sellers to undercut them. Regulation can therefore protect both consumers and reputable businesses.

Experience-Based Lessons From the FDA–Supplement Conflict

The most useful lessons emerge not from political slogans but from what consumers, clinicians, regulators, and responsible manufacturers repeatedly experience in the real world.

The Consumer Experience: A Store Shelf Looks Like Approval

Many shoppers naturally assume that a product displayed by a national retailer has been reviewed for effectiveness. The packaging looks professional, the label contains precise milligram amounts, and the bottle may sit only a few feet from FDA-approved medication.

That visual similarity creates an understandable but incorrect impression. Availability is not proof of FDA approval, and a Supplement Facts panel is not the same thing as evidence that a product delivers its advertised benefit.

A practical consumer habit is to separate three questions: Does the bottle contain what the label claims? Is that amount reasonably safe for this individual? Is there credible evidence that it works for the intended purpose? A shiny label can answer none of them by itself.

The Clinical Experience: “What Supplements Do You Take?” Matters

Doctors and pharmacists frequently discover supplement use only after asking directly. Patients may omit products because they do not consider vitamins, powders, teas, or herbal capsules to be medications.

That omission matters. Supplements may interact with prescription drugs, complicate surgery, increase bleeding risk, alter laboratory results, or deliver overlapping doses of the same nutrient. A patient taking a multivitamin, a “bone support” formula, and a sleep blend may unknowingly consume the same ingredient three times.

The best practical approach is not ridicule. Dismissing every supplement can make patients less willing to disclose what they take. A more productive conversation asks what the product is, why the person uses it, what evidence supports it, and whether a safer or more effective alternative exists.

The Manufacturer Experience: Responsible Companies Pay More

Reputable supplement companies spend money on supplier qualification, identity testing, contamination screening, stability work, accurate labeling, adverse-event systems, and good manufacturing practices. Those expenses are invisible to shoppers comparing two bottles online.

A less responsible competitor can offer a cheaper product by skipping those steps and investing instead in dramatic advertising. When regulators lack product visibility or enforcement resources, honesty becomes a financial disadvantage.

This is why some industry groups support greater transparency. Clear listing and enforcement requirements can make it harder for anonymous sellers and adulterated products to hide beside legitimate brands.

The Regulatory Experience: Post-Market Action Is Slow

When a harmful product appears, regulators must identify it, gather evidence, trace its manufacturer, evaluate reports, inspect facilities, test samples, issue warnings, and sometimes pursue seizure or litigation. During that process, online sellers may rename the product, alter the label, or reopen under another storefront.

Expecting post-market enforcement to catch everything is like installing a smoke detector only after smelling smoke from three neighborhoods away.

The Political Experience: “Freedom” Is an Effective Sales Word

Rep. Burton understood that “consumer freedom” is emotionally stronger than “interpretation of Section 413(a)(2).” Industry campaigns often frame additional oversight as an attempt to ban vitamins, even when a proposal concerns notification, labeling, or substantiation.

Regulators make the opposite communication mistake when they explain policy exclusively through dense technical documents. When one side offers a rallying cry and the other offers a 100-page PDF, the PDF rarely wins the bumper-sticker contest.

The lasting lesson is that access and safety are not enemies. Consumers can retain broad access to supplements while demanding accurate ingredients, honest claims, visible manufacturers, and reasonable evidence of safety. Choice becomes more meaningful when buyers know what they are choosing.

Conclusion: The Rescue Consumers Actually Need

Rep. Dan Burton’s Dietary Supplement Protection Act did not become law, but it captured a recurring pattern in American supplement policy. The FDA attempts to clarify or strengthen oversight; parts of the industry warn that access is under attack; lawmakers introduce a rescue measure; and the public is invited to choose between freedom and safety as though it cannot have both.

The real question is not whether consumers should be allowed to buy dietary supplements. They should. The question is whether companies selling biologically active products should provide basic information, follow manufacturing standards, support objective claims, and demonstrate reasonable safety when introducing new ingredients.

That is not a war on vitamins. It is the modest proposition that health products should arrive with more evidence than enthusiasm.